Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A, KEYNOTE-B15/EV-304 Investigators.

Open source

DOI: 10.1056/nejmoa2601486
Published: 2026-07-01
Container: N Engl J Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2601486,
  title = {Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.},
  author = {Galsky MD and  Valderrama BP and  Maruzzo M and  Font A and  Ciuleanu T and  Chatzkel J and  Koie T and  Hoimes CJ and  Puente J and  Zakharia Y and  Rosenbaum E and  Boehm K and  Loriot Y and  Bedke J and  Powles TB and  Necchi A and  Wiechno P and  Álvarez-Fernández C and  Kim TH and  Oliveira N and  Flaig TW and  Wirtz HS and  Mihm M and  Huang Q and  Rogiers A and  Homet Moreno B and  Gómez de Liaño A and  KEYNOTE-B15/EV-304 Investigators.},
  year = {2026},
  journal = {N Engl J Med},
  doi = {10.1056/nejmoa2601486},
  url = {https://doi.org/10.1056/nejmoa2601486}
}

RIS

TY  - JOUR
TI  - Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
AU  - Galsky MD
AU  -  Valderrama BP
AU  -  Maruzzo M
AU  -  Font A
AU  -  Ciuleanu T
AU  -  Chatzkel J
AU  -  Koie T
AU  -  Hoimes CJ
AU  -  Puente J
AU  -  Zakharia Y
AU  -  Rosenbaum E
AU  -  Boehm K
AU  -  Loriot Y
AU  -  Bedke J
AU  -  Powles TB
AU  -  Necchi A
AU  -  Wiechno P
AU  -  Álvarez-Fernández C
AU  -  Kim TH
AU  -  Oliveira N
AU  -  Flaig TW
AU  -  Wirtz HS
AU  -  Mihm M
AU  -  Huang Q
AU  -  Rogiers A
AU  -  Homet Moreno B
AU  -  Gómez de Liaño A
AU  -  KEYNOTE-B15/EV-304 Investigators.
PY  - 2026
JO  - N Engl J Med
DO  - 10.1056/nejmoa2601486
UR  - https://doi.org/10.1056/nejmoa2601486
ER  -

APA

MD, G., BP, V., M, M., A, F., T, C., J, C., T, K., CJ, H., J, P., Y, Z., E, R., K, B., Y, L., J, B., TB, P., A, N., P, W., C, Á., TH, K., N, O., TW, F., HS, W., M, M., Q, H., A, R., B, H. M., A, G. D. L., & Investigators., K. (2026). Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.. N Engl J Med. https://doi.org/10.1056/nejmoa2601486

Source records

europe-pmc · retrieved 2026-09-25T17:53:49.196Z